Phenytoin vs Zonisamide (Zonegran)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline

Phenytoin

Marketed by Viatris and partners

Approved in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Zonisamide (Zonegran)

Marketed by Advanz Pharma and partners

Approved in Epilepsysmall molecule
Weak signal

NCT00056576 · Phase 3 · completed

Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.

Reported efficacy

Percentage of Participants Remaining in the Study at Each Visit (At 3, 6, 9, 12, 15, 18, 21, 24, and 27 months): Long-term extension; the registered primary was retention in the study at each visit, with no formal test. Retention at 12 months: zonisamide 58.4% (n=137) vs carbamazepine 61.4% (n=158) (CT.gov posted results). (not_applicable)

Result source: NCT00848549

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointPhenytoinZonisamide (Zonegran)
Seizure frequency, % change—Not posted · NCT00210782-48.4% vs -26.6%−21.8 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • -32.7% vs -35.6% wk 16 · n 24 · Phase 3 · primary NCT00292461
50% responder rate—Not posted · NCT0021078248.6% vs 34.9%+13.7 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • 45.8% vs 45.8% wk 16 · n 24 · Phase 3 · secondary NCT00292461
Seizure freedom—Not posted · NCT002107821.8% vs 2.8%−1 vs placebo100 mg · wk 16 · n 111NCT00327717

Seizure frequency, % change

Phenytoin
—Not posted · NCT00210782
Zonisamide (Zonegran)
-48.4% vs -26.6%−21.8 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • -32.7% vs -35.6% wk 16 · n 24 · Phase 3 · primary NCT00292461

50% responder rate

Phenytoin
—Not posted · NCT00210782
Zonisamide (Zonegran)
48.6% vs 34.9%+13.7 vs placebo100 mg · wk 16 · n 111NCT00327717
1 other result
  • 45.8% vs 45.8% wk 16 · n 24 · Phase 3 · secondary NCT00292461

Seizure freedom

Phenytoin
—Not posted · NCT00210782
Zonisamide (Zonegran)
1.8% vs 2.8%−1 vs placebo100 mg · wk 16 · n 111NCT00327717
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Phenytoin: 3 of 4 rows · Zonisamide (Zonegran): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPhenytoinZonisamide (Zonegran)
Dropout rate
38.2%a
NCT00510783 · Phase 4 · registry result, not featured evidence
42.9%Zonisamidea
NCT00848549 · Phase 3 · monotherapy
show 12 more results
—Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
—Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
27.3%
NCT01140867 · Phase 4 · registry result, not featured evidence
31.7%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
24.6%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
29.2%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
33.3%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
13.1%
NCT00566254 · Phase 3 · registry result, not featured evidence
42.9%
NCT00477295 · Phase 3 · registry result, not featured evidence
29.4%
NCT00292461 · Phase 3 · registry result, not featured evidence
7.5%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT00510783 · Phase 4 · registry result, not featured evidence
11%Zonisamidea
NCT00848549 · Phase 3 · monotherapy
show 12 more results
—Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
—Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
18.2%
NCT01140867 · Phase 4 · registry result, not featured evidence
3.3%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
3.1%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
—
NCT00855738 · Phase 4 · registry result, not featured evidence
2.8%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
4.2%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
0.9%
NCT00566254 · Phase 3 · registry result, not featured evidence
11%
NCT00477295 · Phase 3 · registry result, not featured evidence
11.8%
NCT00292461 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Serious AEs
0%a
NCT00510783 · Phase 4 · registry result, not featured evidence
—Zonisamidea
NCT00848549 · Phase 3 · monotherapy
show 12 more results
5.3%Zonisamide (Base Study 310, NCT004
NCT00848549 · Phase 3 · monotherapy
5.1%Zonisamide (Extension Study 314, N
NCT00848549 · Phase 3 · monotherapy
1.7%
NCT01140867 · Phase 4 · registry result, not featured evidence
1.7%high dose
NCT01127165 · Phase 4 · registry result, not featured evidence
3.1%low dose
NCT01127165 · Phase 4 · registry result, not featured evidence
0%
NCT00855738 · Phase 4 · registry result, not featured evidence
9.7%Zonisamide (Zonisamide During Core
NCT01136954 · Phase 3 · registry result, not featured evidence
4.2%Zonisamide(Placebo During Core Stu
NCT01136954 · Phase 3 · registry result, not featured evidence
3.7%
NCT00566254 · Phase 3 · registry result, not featured evidence
5.3%
NCT00477295 · Phase 3 · registry result, not featured evidence
0%
NCT00292461 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT00327717 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence
a
headache 10.3%
decreased appetite 7.8%
weight decreased 6.8%
NCT00848549 · Phase 3 · monotherapy
show 11 more results
weight decreased 5.8%
headache 4.4%
decreased appetite 0%
NCT00848549 · Phase 3 · monotherapy
dizziness 28.1%
somnolence 24%
anorexia 18.2%
NCT01140867 · Phase 4 · registry result, not featured evidence
high dose
dizziness 5%
micturition disorder 5%
somnolence 5%
NCT01127165 · Phase 4 · registry result, not featured evidence
low dose
anorexia 4.6%
fatigue 3.1%
somnolence 3.1%
NCT01127165 · Phase 4 · registry result, not featured evidence
somnolence 7.5%
weight increased 5%
dizziness 2.5%
NCT00855738 · Phase 4 · registry result, not featured evidence
nasopharyngitis 12.5%
headache 9.7%
weight decreased 8.3%
NCT01136954 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.3%
weight decreased 8.3%
decreased appetite 6.9%
NCT01136954 · Phase 3 · registry result, not featured evidence
decreased appetite 6.5% (placebo 4%)
headache 6.5% (placebo 7%)
nasopharyngitis 5.6% (placebo 9%)
NCT00566254 · Phase 3 · registry result, not featured evidence
headache 10.3%
decreased appetite 7.8%
weight decreased 6.8%
NCT00477295 · Phase 3 · registry result, not featured evidence
hepatic enzyme abnormal 8.8%
blood alkaline phosphatase increased 5.9%
dizziness 5.9%
NCT00292461 · Phase 3 · registry result, not featured evidence
100 mg
anorexia 18.3% (placebo 5.1%)
somnolence 12.5% (placebo 14.4%)
headache 10.8% (placebo 5.1%)
NCT00327717 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Phenytoin

Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted

Zonisamide (Zonegran)

Seizure Free 24 32.3% (n=281) vs 35.2% (n=300) Carbamazepine @ 117wk
responder rate · % of participants
Extension (open-label)
NCT00848549 · Phase 3 · monotherapy
QOLIE-31-P 4.697 vs 7.101 Carbamazepine score @ 0wk
absolute change · score
NCT00848549 · Phase 3 · monotherapy
show 4 more results
6.101 vs 10.956 Carbamazepine score @ 26wk
NCT00848549 · Phase 3 · monotherapy
8.602 vs 11.687 Carbamazepine score @ 52wk
NCT00848549 · Phase 3 · monotherapy
4.287 vs 1.902 Carbamazepine score @ 78wk
NCT00848549 · Phase 3 · monotherapy
-0.292 vs 15.849 Carbamazepine score @ 117wk
NCT00848549 · Phase 3 · monotherapy
Partial Onset Seizure Frequency -16.35% (n=102) @ 16wk
percent change · % of baseline
No placebo or comparator arm
NCT01140867 · Phase 4 · registry result, not featured evidence
Seizure-free 24.51% (n=102) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT01140867 · Phase 4 · registry result, not featured evidence
show 2 more results
63.1% (n=49) @ 24wklow dose
NCT01127165 · Phase 4 · registry result, not featured evidence
57.6% (n=41) @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Seizure 50 61.76% (n=102) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT01140867 · Phase 4 · registry result, not featured evidence
Kwisc III -1.3913 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
0.1071 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Kcbc -5.259 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.611 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
K-QOLCE 4.7931 score @ 24wklow dose
absolute change · score
No placebo or comparator arm
NCT01127165 · Phase 4 · registry result, not featured evidence
show 1 more result
1.2286 score @ 24wkhigh dose
NCT01127165 · Phase 4 · registry result, not featured evidence
Seizure 50 55.6% (n=72) @ 59wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
56.9% (n=72) @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure Frequency -3.8 Seizures @ 59wk
absolute change · Seizures
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
-4.7 Seizures @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure Frequency -64.6% (n=72) @ 59wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT01136954 · Phase 3 · registry result, not featured evidence
show 1 more result
-67.9% (n=72) @ 59wk
NCT01136954 · Phase 3 · registry result, not featured evidence
Seizure 50 50% (n=107) vs 31% (n=100) placebo @ 20wk
responder rate · % of participants
Maintenance
NCT00566254 · Phase 3 · registry result, not featured evidence

+ 15 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Phenytoin's landscape · Zonisamide (Zonegran)'s landscape